Cardiology

Top Story

PARAMETER: HF therapy superior to olmesartan for systolic hypertension in some elderly patients

September 2, 2015

Read the Perspective from José Ramón González-Juanatey, MD, PhD, FESC, FACC

LONDON — Elderly patients with systolic hypertension and suspected arterial stiffness had lower central systolic BP and pulse pressure when assigned a therapy recently approved for treatment of HF than when assigned olmesartan, according to results from the PARAMETER study.

Researchers assigned 454 patients aged 60 years or older with systolic BP ≥ 150 mm Hg and pulse pressure > 60 mm Hg, a surrogate for arterial stiffness, to receive sacubitril/valsartan (Entresto, Novartis) 400 mg/day or olmesartan 40 mg/day for 12 weeks, and then to be supplemented with other BP-lowering therapies for up to 52 weeks if systolic BP was not controlled at 12 weeks.

Meeting News Coverage

Thrombectomy improves neurological recovery after acute stroke

September 1, 2015
LONDON — Use of thrombectomy to retrieve larger thrombi improved neurological recovery at discharge in patients with acute ischemic stroke, according to a substudy…
VIDEO: The future of gene transfer for treatment of HF Meeting News CoverageVideo

VIDEO: The future of gene transfer for treatment of HF

September 1, 2015
LONDON — In this video, Barry H. Greenberg, MD, from the University of California, San Diego, provides investigator insight on the future of percutaneous…
Uwe Zeymer, MD Meeting News CoveragePerspective

PRESERVATION I: Bioabsorbable cardiac matrix does not prevent LV remodeling, HF

September 1, 2015
LONDON — Deployment of an inert bioabsorbable cardiac matrix did not prevent left ventricular remodeling or occurrence of HF in patients with acute MI and large…
VIDEO: New diagnostic strategy explored in PLATFORM trial Meeting News CoverageVideo

VIDEO: New diagnostic strategy explored in PLATFORM trial

September 1, 2015
LONDON — In this video, Pamela S. Douglas, MD, of Duke Clinical Research Institute and Duke University School of Medicine, outlines the findings of PLATFORM, a…
More News Headlines »
CME
PCI in ACS: Deciding Among Clopidogrel, Prasugrel, or Ticagrelor

PCI in ACS: Deciding Among Clopidogrel, Prasugrel, or Ticagrelor

This activity is supported by an educational grant from Daiichi Sankyo, Inc. and Lilly USA, LLC

It is estimated that in the United States, each year, over 780,000 persons will experience an acute coronary syndrome…
More »
Meeting News Coverage Video
VIDEO: New diagnostic strategy explored in PLATFORM trial

VIDEO: New diagnostic strategy explored in PLATFORM trial

September 1, 2015
LONDON — In this video, Pamela S. Douglas, MD, of Duke Clinical Research Institute and Duke University School of…
More »
CME
Cardiology Case Consults

The Patient with Obesity

No commercial support for this activity.

This CME activity will focus on the diagnosis and management of patients with obesity.
More »
morganatic-roan
morganatic-roan